No Data
A Novel Broad-Spectrum Antiviral With Activity Against RSV
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. , a global
NanoViricides CEO Discusses NV-387's Broad-spectrum Antiviral Potential | NYSE-A:NNVC
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. , a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's
NanoViricides to Showcase Lead Drug Asset's Progress at EF Hutton Annual Global Conference | NYSE-A:NNVC
NanoViricides Reports Research With NV-387 Showing Promising Results Against Multiple Viruses | NYSE-A:NNVC
NanoViricides Reports Breakthrough in Treating Airborne Viruses, Boosting Lifespan in Infected Mice
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against or